Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 12/20 | 0.48 |
| ▸ | GAA | P10253 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700320 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL28073275 | 0.86 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL1956333 | 0.86 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL28131025 | 0.86 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL1700253 | 0.82 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL2483201 | 0.82 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL1700252 | 0.82 | MAPT (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL27910633 | 0.81 | HCAR3 (0.54) | SMN1; SMN2MAPTGAAALDH1A1LMNA | |
| SCHEMBL25416297 | 0.81 | WNT3 (0.40) | MAPTGAAALDH1A1LMNAHTT | |
| SCHEMBL1700217 | 0.80 | KMT2A (0.50) | SMN1; SMN2MAPTGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897038-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-108175749-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20200231566-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2376480-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9315488-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160009687-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-9174982-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9125913-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-8563735-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8546399-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BRUNCKO MILAN (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 1906/4885MAPT 3831/4885GAA 1838/4885 |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 2213/4885MAPT 3942/4885GAA 2007/4885 |
| US-20100305122-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2670/4885MAPT 3890/4885GAA 2795/4885 |
| US-20130267514-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2848/4885MAPT 4105/4885GAA 2733/4885 |
| US-20120190688-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2848/4885MAPT 4105/4885GAA 2733/4885 |
| US-20200231566-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2670/4885MAPT 3890/4885GAA 2795/4885 |
| US-20160009687-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 2213/4885MAPT 3942/4885GAA 2007/4885 |
| US-20110124628-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2848/4885MAPT 4105/4885GAA 2733/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | SMN1; SMN2 2213/4885MAPT 3942/4885GAA 2007/4885 |
| US-20130267534-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | SMN1; SMN2 2848/4885MAPT 4105/4885GAA 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.